Paul Ichiro Terasaki was an American scientist and surgeon whose work fundamentally changed organ transplantation. Born in Los Angeles in 1929, he built a career that combined laboratory innovation with clinical application. He served for many years at the UCLA School of Medicine, eventually holding the title of Professor Emeritus of Surgery. Terasaki is widely credited with introducing practical, laboratory-based human leukocyte antigen (HLA) testing that made routine matching of donors and recipients possible.

Major contribution: the microcytotoxicity test

In 1964 Terasaki developed the microcytotoxicity test, also called the microlymphocytotoxicity assay, a simple, reproducible method for identifying HLA differences between individuals. The technique required only about one microliter of antisera per test well and allowed laboratories to screen many antigens rapidly. By making HLA typing inexpensive and scalable, the assay became a standard tool for transplant centers and tissue-typing laboratories worldwide, improving the ability to predict and reduce immune rejection.

Scientific context and significance

The HLA system is a group of proteins on cell surfaces that help the immune system distinguish self from non-self. Mismatches in HLA between donor and recipient increase the risk of graft rejection. Terasaki's assay allowed clinicians to match transplants more closely on immunological grounds, which contributed to better graft survival and informed immunosuppressive strategies. His work linked laboratory immunology to measurable clinical outcomes and helped establish HLA typing as a routine part of transplant evaluation.

Career and legacy

Terasaki published extensively on transplant immunology and HLA matching and was known for translating laboratory advances into clinical practice. He trained many students and influenced the organization of tissue-typing services and registries. While the basic cytotoxicity assay has been largely supplemented by more modern molecular methods, Terasaki's innovation paved the way for current high-resolution genetic typing and compatibility testing used in kidney, heart, liver and other organ transplants.

Recognition and later life

Recognized internationally for his contributions to transplantation, Terasaki received honors and continued to be active in research and philanthropy related to transplantation and immunology. Biographical summaries and profiles describe his impact on both laboratory technique and clinical policy; see a concise scientist profile or a more detailed research summary for further reading. Notices of his passing appeared in medical and local outlets, including an obituary published after his death in Beverly Hills in January 2016 at age 86.

Notable distinctions and continuing relevance

  • Introduced a practical method for HLA typing that became a worldwide standard.
  • Helped integrate immunogenetic testing into transplant medicine and allocation policies.
  • Laid groundwork for modern molecular HLA typing and compatibility algorithms used today.

For institutional context on his academic affiliations and regional ties, see references to UCLA and his birthplace in UCLA School of Medicine, Los Angeles, and broader California materials. Researchers and transplant professionals continue to cite Terasaki's early work as a turning point that made systematic donor–recipient matching practical and routine.